Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Authors :: S. N. Tereshchenko
M. V. Shestakova
F. T. Ageev
G. R. Galstyan
A. S. Galyavich
M. G. Glezer
I. V. Zhirov
Yu. A. Karpov
Zh. D. Kobalava
S. T. Matskeplishvili
Source :: Российский кардиологический журнал, Vol 25, Iss 5 (2020)
Publication Year :: 2020
Publisher :: «FIRMA «SILICEA» LLC, 2020.
Abstract: Relationships and Activities. The Council of Experts was supported by AstraZeneca.

Subjects :: heart failure with reduced ejection fraction
dapa-hf trial
dapagliflozin
Diseases of the circulatory (Cardiovascular) system
RC666-701

Full Text Access

Tools